The second issue of Representations, a limited series exploring neurotech's evolving business frontier, produced in partnership with PL Neuro.
This issue tracks the commercial activity behind the field's rise. A new Q1 2026 BCI market map — compiled with PL Neuro — tallies $653M in new capital led by Merge Labs and Science Corp, Boston Scientific's $14B acquisition of Penumbra, 18+ new clinical partnerships, and Chinese BCI investment crossing $100M. At this pace, 2026 BCI funding is on track to hit $2B, aiming far beyond today's $8.8B neurotech market.
The edition also digs into infrastructure and leadership as the forces shaping a sustainable cybernetic era. It reads the first of Protocol Labs' BCI Roadmap Series — its diagnosis of the FDA–reimbursement disconnect and its five-year action plan — and closes with the inaugural Juan Benet Podcast episode featuring Science Corp's Max Hodak on restoring sight, growing neurons on silicon, and expanding human intelligence.
Representations is written by Naveen Rao of Neurotech Futures, in partnership with PL Neuro.
Read the full issue: on Neurotech Futures